Sjögren syndrome successfully treated with oxygen-ozone auto-hemotherapy (O2-O3-AHT). A case report
Valdenassi L, Rossi E, Corsetti MT, et al. European Review for Medical and Pharmacological Sciences, 2022.
- Study type
- Case report
- People studied
- 1 person
- Population
- 69-year-old woman with primary Sjögren syndrome
- Published
- 2022, European Review for Medical and Pharmacological Sciences
- Identifiers
- PMID 36066166, DOI 10.26355/eurrev_202208_29530
What the authors reported
A 69-year-old woman with primary Sjögren syndrome was given two series of three weekly oxygen-ozone autohemotherapy sessions; the authors report that she improved after two sessions and that her ocular dryness, fatigue, and pain rapidly disappeared.
What limits this result
One patient, no control group, and no blinding; cannot separate any ozone effect from the natural course of the disease or other concurrent care. The first and last authors list the Italian Society of Oxygen-Ozone Therapy (SIOOT), four authors a university master's course in oxygen-ozone therapy, and the paper thanks SIOOT staff for technical support.
Other ozone methods, such as major autohemotherapy, that clinics cite in support of EBO2. A result for one method does not transfer automatically to another. One study rarely settles a medical question; our guides weigh each paper against the rest of the evidence.
How the study was done
- Design
- Case report
- Setting
- First-listed affiliation: Italian Society of Oxygen-Ozone Therapy (SIOOT), Gorle (BG), Italy
- Read from
- Read from the full text of the paper. Read on September 28, 2026.
Sources: The paper at europeanreview.org, Abstract on PubMed
Study arms
| Group | Participants | What they received |
|---|---|---|
| 69-year-old female outpatient with primary Sjögren syndrome (pSS) | Not reported | Oxygen-ozone autohemotherapy (O2-O3 AHT); see protocol |
Source: The paper at europeanreview.org
Procedure as reported
- Ozone concentration
- 45 μg/ml
- Blood volume
- 100 ml of blood
- Sessions
- One session/week for a total of six discontinued weeks in two routes, with 10 days lag (total ozone dosage 4.5 mg per session)
- Anticoagulant
- 11 ml of 3.8% Na-citrate
In the paper's own units, not converted.
Source: The paper at europeanreview.org
What it measured
- Ocular dryness, fatigue and pain (abstract)
- Improved with only 2 sessions; ocular dryness, fatigue and pain rapidly disappeared
- Orbital erythema, arthralgia and dryness syndrome
- Complete regression obtained (Figure 3)
- 16-item Patient-Reported Arthralgia Inventory (PRAI)
- Arthralgia reduced from 135 to 91 (p = 0.00000147)
- 9-item Fatigue Severity Scale (FSS)
- Fatigue reduced by 75% (p = 0.0000213)
- Antinuclear antibody (ANA) titer
- Reduced to 1:160 (Figure 2)
- Authors' conclusion (abstract)
- Ozone in the therapy of Sjögren syndrome described as a straightforward, affordable and feasible approach to treat primary Sjögren syndrome without significant side effects
Sources: Abstract on PubMed, The paper at europeanreview.org
Safety as reported
Conclusion describes the approach as being without significant side effects; no individual adverse events are describedThe use of ozone in the therapy of SS is a straightforward, affordable and feasible approach to treat primary Sjögren syndrome without significant side effects.
Source: Abstract on PubMed
Follow-up
ANA test shown in Figure 2 was done following 1 year of treatment
Source: The paper at europeanreview.org
Funding and conflicts
The authors declare no conflict of interest
Source: The paper at europeanreview.org
Where we cite this study
Does EBO2 (EBOO) Work? The Evidence, Study by Study
Every study in our EBO2 (EBOO) library in one place: design, size, what was measured and found, its limits, and a check for any study a clinic cites.
EBO2 (EBOO) for Autoimmune Conditions: Clinic Claims, the MS and Sjögren's Studies, and Standard Care
What clinics claim about EBO2 (EBOO) for autoimmune disease, what the MS, Sjögren's and RA ozone studies measured, and what NIH describes as care.
EBO2 (EBOO), Blood Thinners, and Other Medicines: What the Sources Say and What to Ask
How EBOO circuits are kept from clotting, what heparin's FDA label warns, what clinics say about blood thinners, and what no source has studied.
How Many EBO2 (EBOO) Sessions Do You Need? What Clinics Recommend and What Studies Used
How many EBO2 (EBOO) sessions US clinics recommend, from our dataset of clinic pages, set against the course lengths published studies actually used.